iL‒CURRENT
February 25, 2026
Dr. Hossein Eslami Amirabadi: "Understanding the real market problem is an art."
At the forum GENESIS 26 – The LIFE SCIENCE TECH DAY Dr. Hossein Eslami Amirabadi will speak about innovative approaches to advancing preclinical cell models in his presentation “Scalable Platform with Physiological Flow“.
In the iL expert interview, the scientist and entrepreneur - co-founder and Chief Technology Officer (CTO) of the start-up and the cell culture platform ARTIC Technologies based in Eindhoven, the Netherlands - provides diverse insights into his technology, the entrepreneurial decisions, and challenges at the interface between research and the market.
In the iL expert interview, the scientist and entrepreneur - co-founder and Chief Technology Officer (CTO) of the start-up and the cell culture platform ARTIC Technologies based in Eindhoven, the Netherlands - provides diverse insights into his technology, the entrepreneurial decisions, and challenges at the interface between research and the market.
Dr. Hossein Eslami Amirabadi from ARTIC Technologies in the Netherlands. Image: ARTIC Technologies
Five Questions for … Hossein Eslami Amirabadi
Mr. Amirabadi, ARTIC Technologies is a spin-off of the Eindhoven University of Technology. What was the most critical step in moving from academic research to a market-ready life science product?
Hossein Eslami Amirabadi: License deal with the university is always a challenge but for me, the starting application and market to start a technology-push company was the most critical step for me. On the one hand, you have to know the potential of your technology very well, and on the other hand you should know problems in a certain market that are large enough. At the same time, you have to evaluate whether your technology can solve those problems.
Which core technological innovation at ARTIC currently gives you the greatest competitive advantage?
Amirabadi: Scalable model to culture and test different cell models with physiological flow. We know that physiological flow is relevant in many tissue models and improves the predictivity of those models. But in current systems with relevant flows are complex to use and not compatible with day-to-day work-flow of the industry and academia. This has resulted in low adoption of organ-on-chip systems. ARTIC creates physiological flow in traditional cell culture well plates without changing the format and operation of such well plates. We do this by our proprietory technology called Magnetic Artificial Cilia.
"We are technology-driven."
You are responsible for both technological development and market strategy. Where do you see the greatest tensions between technological excellence and successful commercial viability?
Amirabadi: Very good question! We are technology push and as a scientist you want to convince yourself that certain problems exist, a sort of confirmatioin bias that makes you not hear the complete truth! Commercial viability means to start from the problem and see whether you can offer a unique solution that nobody else can offer. Weh ave pivotted already 2 times and still continuously commiunicating to end-users to see whether our solution can solve their problems. We see already in the field that early decisions in the development of the technology can have enormous influence on the adoption of the technology. So we started early, before further development of our technology, we let our ideas be criticized by experts and indstrial experts. Tried to stay naive and only listen tot he problems. Understanding the real problem in the market and objectively asking yourself whether you can solve is an art.
The dedicated team at ARTIC Technologies, center: co-founder and CTO Dr. Hossein Eslami Amirabadi. Image: ARTIC Technologies
What role do industry partners - and in particular an institution such as Health Holland in The Hague - play in the development process of your start-up?
Amirabadi: Big big role, we are lucky to be in the Netherlands to have so much systematic government support and Health Holland is a front-runner. They drive the direction of our company. Also other partners including the end-users (pharmaceutical companies, biotech and CRO’s) as well as manufacturing partners. We are also lucky to be in the Eindhoven Region (or the so called Brainport region) to have such a strong manufacturing industry around.
You are a speaker in the session on innovative materials at GENESIS 26. What outcomes and new connections are you hoping for ARTIC to gain from this event?
Amirabadi: I look for industrial or academic connections who would like to test our prototype in their labs. I also hope that I can connect to scientists and listen to the challenges they face in their companies or academic groups.
About the person
Hossein Eslami Amirabadi, PhD, from ARTIC Technologies is a scientist-entrepreneur, passionate about creating impact, like translating academic solutions to impactful products, interested in interdisciplinary interactions, enough positive energy for myself and co-workers, persevering, finish what started, into microphysiological systems, good at strategic thinking.
About ARTIC Technologies
ARTIC Technologies enables scientists to create better cell models for preclinical drug research. Our first product is a scalable cell culture well plate with physiological flow. The well plate is equipped with our patented technology, Magnetic Artificial Cilia, developed at Eindhoven University of Technology by one of the pioneers of the field, Professor Jaap den Toonder.
by Joachim Klaehn
Event details
GENESIS 26 – The LIFE SCIENCE TECH DAY
Topic:
Engineering Next-Generation Platforms for Disease Modeling and Drug Screening
Note:
GENESIS 26 – The LIFE SCIENCE TECH DAY will be held in English.
When?
Thursday, March 12, 2026 (9:30 a.m. – 5:00 p.m.)
Where?
FRAUENBAD the Old Indoor Swimming Pool in Heidelberg, Bergheimer Straße 45, 69115 Heidelberg
Participation Fee:
70.00 euros
Contact:
Dr. Reza Taale, Cluster Manager, Tel.: +49 (0) 157 806 444 92, Email: reza.taale@innovationlab.de
Dr. Kerstin Zyber‒Bayer
Senior Manager, Strategic Marketing & Communications
This website is not part of the Facebook website or Facebook Inc. Furthermore, this website is not supported by Facebook in any way. Facebook is a trademark of Facebook, Inc. We use Google remarketing pixels/cookies on this website to communicate with visitors to our website again and ensure that we can reach them with relevant news and information in the future. Google places our ads on third-party websites on the internet to communicate our message and reach the right people who have shown interest in our information in the past.